The latest news:

• ReACT: Long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma         Impressive long term survival state presented at the SNO conference of Rindopepimut plus Avastin vs. Avastin alone for recurrent Glioblastoma patients. Highlight: at 2 years the Rindopeimut + Avastin group had 25% of patients alive. The Avastin alone group had 0% alive.   This is just a simple shot in the arm which adds no significant side effects - just local reaction at the injection site like a flu shot.
  



• Phase I/II Study of Dianhydrogalactitol (Val-083) in Patients with Recurrent Malignant Glioma        This small study was in patients with glioblastoma multiforme who failed Temodar and Avastin. In general, patients who failed these 2 treatments live an average of an additional 2 months without further treatment, or 5.2 months with salvage therapies.  With high dose Val-083, median survival was 9.2 more with 1/3 of the patients being alive at the 12 month point. Pretty good results in a very bad patient population.
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants